Patents Issued in January 25, 2024
  • Publication number: 20240024270
    Abstract: A composition of chlorogenic acids and method of its use and manufacture in the treatment of metabolic disorders. The composition can be obtained from sunflower seed extract, including Helianthus annulus seeds.
    Type: Application
    Filed: July 21, 2023
    Publication date: January 25, 2024
    Inventor: Kodimule Shyam PRASAD
  • Publication number: 20240024271
    Abstract: The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 25, 2024
    Inventor: O'Neil W. Guthrie
  • Publication number: 20240024272
    Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
    Type: Application
    Filed: July 24, 2023
    Publication date: January 25, 2024
    Applicant: MBI Distributing
    Inventor: Ned L. Jensen
  • Publication number: 20240024273
    Abstract: Provided herein is 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate or pharmaceutically acceptable salts thereof. Furthermore, for use and methods in the treatment of various pains and inflammation, in particular osteoarthritis with pharmaceutical compositions, treatment kits and devices comprising 2-(diethylamino) ethyl 2-(4-isobutylphenyl) propionate and/or pharmaceutically acceptable salts thereof, as well as dosage forms, dosages, and methods of use thereof through topical administration, for treatment of various pains and inflammation, in particular osteoarthritis, are disclosed.
    Type: Application
    Filed: June 4, 2021
    Publication date: January 25, 2024
    Inventors: Chongxi Yu, Lina Xu
  • Publication number: 20240024274
    Abstract: The present patent application relates to O-acetylserine, or a salt or derivative thereof, for use in the treatment and/or prevention of glucose intolerance and/or one or more diseases associated with glucose intolerance in an individual. The invention also relates to a composition for use in the treatment and/or prevention of glucose intolerance and/or one or more diseases associated with glucose intolerance in an individual, comprising an O-acetylserine, or a salt or derivative thereof, and a physiologically acceptable vehicle.
    Type: Application
    Filed: October 7, 2021
    Publication date: January 25, 2024
    Inventors: Christine DELORME, Véronique DOUARD
  • Publication number: 20240024275
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Application
    Filed: May 9, 2023
    Publication date: January 25, 2024
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • Publication number: 20240024276
    Abstract: Compositions and methods for improving cardiac structure and/or function in subjects in need thereof. The methods include administering to a subject a succinate dehydrogenase inhibitor in an amount and for a time effective to elicit an improvement in cardiac structure and/or function. The subjects include subjects suffering from cardiac damage, such as damage resulting from myocardial infarction or other cardiac events. Improvements in cardiac function include one or more of an increase in cardiomyocyte proliferation, an increase in ejection fraction, an increase in fractional shortening, a decrease in left ventricle internal diameter diastole, and a decrease in left ventricle internal diameter systole. Improvements in cardiac structure include one or more of decreased fibrosis, an increase in myocardial thickness, an increase in coronary artery formation, an increase in capillary density, an increase in revascularization, and a decrease in myocardial lesion size.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 25, 2024
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Ahmed I MAHMOUD, Jiyoung Bae
  • Publication number: 20240024277
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: February 24, 2023
    Publication date: January 25, 2024
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Publication number: 20240024278
    Abstract: The present invention concerns compositions containing ranitidine or one of its pharmaceutically acceptable salts having low iron species content. The present invention also concerns compositions having low content of iron species that are not under complexed form with a chelating agent and/or having low content of iron species that are partially or completely under complexed form with a chelating agent and/or having low content of iron species that are under complexed form with a chelating agent other than ranitidine and/or having low content of complexes formed between ranitidine and iron species. The present invention also concerns a process for the preparation of said compositions. The present invention also concerns the second medical use of said compositions.
    Type: Application
    Filed: December 2, 2021
    Publication date: January 25, 2024
    Inventors: Alain DLUBALA, France Emmanuelle THOLÉ
  • Publication number: 20240024279
    Abstract: Provided herein are methods of reducing the weight loss and/or increasing the weight of a feline in need thereof, said methods include administering to a feline in need thereof a total daily dosage of about 2 to 50 mg of Compound 1, having the formula: or a pharmaceutically acceptable form thereof. Also provided herein are methods of managing the disease of a feline with diabetes mellitus and elevated IGF-1 concentration.
    Type: Application
    Filed: April 6, 2023
    Publication date: January 25, 2024
    Inventors: Michael HADD, Brian SEED
  • Publication number: 20240024280
    Abstract: A senotherapeutic substance including flavonoids, fatty acids, and, preferably, phenolic acids and/or vitamins. The substance may be used for the manufacture of a medicament for senotherapeutic use.
    Type: Application
    Filed: November 30, 2021
    Publication date: January 25, 2024
    Inventors: Venera RUSSO, Giovanni Mario PITARI, Claudia Giovanna LEOTTA, Mario CORREALE, Paolo CORREALE
  • Publication number: 20240024281
    Abstract: The present invention relates to a method for treating a subject suffering from a liver disease comprising a step of administering said subject with a therapeutically effective amount of an inhibitor of the endoribonuclease activity of IRE1?. Inventors have shown that in livers of tunicamycin-treated BI-1?/? mice aIRE1?-dependent NLRP3 inflammasome activation, an hepatocyte death, a fibrosis and a dysregulated lipid homeostasis that led to liver failure within a week. To test whether the pharmacological inhibition of IRE1? endoribonuclease activity would block the transition to NASH, mice were injected with the small molecule STF-083010 twice a week for 2 weeks towards the end of a 3-month HFD. In BI-1?/? mice, STF-083010 treatment effectively counteracted IRE1? endoribonuclease activity, improving glucose tolerance and rescuing from NASH.
    Type: Application
    Filed: June 2, 2023
    Publication date: January 25, 2024
    Inventors: Beatrice BAILLY-MAITRE RE, Philippe GUAL, Albert TRAN
  • Publication number: 20240024282
    Abstract: The present invention relates to a product which is C-phycocyanin or an extract comprising C-phycocyanin; or alternatively, to compositions comprising said product and one or more pharmaceutically acceptable excipients or carriers, for use in the treatment and/or prevention of peripheral neuropathy.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 25, 2024
    Inventors: Consuelo SAN GABRIEL ALCOLEA, Pere GASCÓN VILAPLANA, Emmanuel BLUM
  • Publication number: 20240024283
    Abstract: Described are compositions and methods for treating polyoma viruses such as JCPyV.
    Type: Application
    Filed: July 20, 2023
    Publication date: January 25, 2024
    Inventors: Walter J. Atwood, Jacob S. Kaiserman
  • Publication number: 20240024284
    Abstract: A pharmaceutical composition contains Indomethacin. The composition is a suppository containing a hard fat as a base material.
    Type: Application
    Filed: July 20, 2022
    Publication date: January 25, 2024
    Inventors: Alessandro GALLI, Simone SARNO, Claudio BELLONI, Antonio GERMANI
  • Publication number: 20240024285
    Abstract: A pharmaceutical composition contains Indomethacin. In particular, the composition is a suppository containing a hard fat as a base material.
    Type: Application
    Filed: July 12, 2023
    Publication date: January 25, 2024
    Applicant: FULTON MEDICINALI S.P.A.
    Inventors: Alessandro GALLI, Simone SARNO, Claudio BELLONI, Antonio GERMANI
  • Publication number: 20240024286
    Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
    Type: Application
    Filed: August 1, 2023
    Publication date: January 25, 2024
    Inventors: Sadasivan VIDYASAGAR, Paul OKUNIEFF, Lurong ZHANG
  • Publication number: 20240024287
    Abstract: An application of Anle138b in a drug for improving diet-induced insulin resistance is provided. Anle138b has obvious improvement effects on both preventing and treating insulin resistance, and can reduce the intake efficiency and the body weight. Besides, Anle138b can effectively improve diet-induced ectopic fat storage and adipose tissue hypertrophy, and the effect of Anle138b on improving insulin resistance is independent of the reduction of food intake.
    Type: Application
    Filed: October 28, 2022
    Publication date: January 25, 2024
    Applicant: The First Affiliated Hospital of Shantou University Medical College
    Inventor: Jie WU
  • Publication number: 20240024288
    Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
    Type: Application
    Filed: July 17, 2020
    Publication date: January 25, 2024
    Inventors: Vasukumar KAKUMANU, David Christian HANLEY, Frank YOCCA, Chetan Dalpatbhai LATHIA, Scott David BARNHART, Lavanya RAJACHANDRAN, Robert RISINGER
  • Publication number: 20240024289
    Abstract: Disclosed herein are methods and composition for treating bipolar disorders and psychosis by administering dexmedetomidine. The methods and composition alleviate mania, hypomania, psychosis, and depression in the subjects, providing improved therapeutic outcomes.
    Type: Application
    Filed: October 8, 2021
    Publication date: January 25, 2024
    Inventors: Frank YOCCA, Robert RISINGER, Michael DE VIVO, Friso POSTMA
  • Publication number: 20240024290
    Abstract: The present disclosure relates to pharmaceutical compositions comprising Compound I, or a pharmaceutically acceptable salt thereof, as the active substance. The pharmaceutical compositions are suitable for use in immediate release pharmaceutical formulations. The pharmaceutical formulations are suitable for use in the treatment of medical conditions in which treatment with agonists of CB1/CB2 receptors are beneficial.
    Type: Application
    Filed: July 12, 2021
    Publication date: January 25, 2024
    Applicant: ARTELO BIOSCIENCES LIMITED
    Inventors: Andrew YATES, Paul DICKINSON, Robert WARD
  • Publication number: 20240024291
    Abstract: Provided herein are methods for treating brain cancers, such as malignant gliomas, particularly glioblastomas. Inhibitors of dihydroorotate dehydrogenase singly or in combination with at least other one small molecule drug acting synergistically with the dihydroorotate dehydrogenase inhibitor are administered to a subject with a brain cancer or brought into contact with brain cancer tumor cells. Administration of a drug regimen of the inhibitor and at least one of the small molecule drugs increases sensitivity of a malignant glioma thereto.
    Type: Application
    Filed: July 19, 2023
    Publication date: January 25, 2024
    Applicant: University of Maryland, Baltimore
    Inventor: Eli E. Bar
  • Publication number: 20240024292
    Abstract: Congenital aniridia is a rare and severe genetic panocular disease characterized by a complete or partial iris defect clinically detectable at birth. The most common form of aniridia occurring in around 90% cases is caused by PAX6 haploinsufficiency. Ataluren eye-drops aim to restore ocular surface PAX6 haploinsufficiency in Aniridia Related Keratopathy (ARK). However, they are currently no ophthalmic solution available forms. The objective of this study was to assess the physicochemical and microbiological stability of ataluren eye-drop 1% in preservative-free low-density polyethylene (LDPE) bottle with an innovative insert that maintains sterility after opening. Because ataluren is a strongly lipophilic compound, the formulation is complex and involves a strategy based on co-solvents in an aqueous phase or an oily formulation capable of totally dissolving the active ingredient.
    Type: Application
    Filed: December 13, 2021
    Publication date: January 25, 2024
    Inventors: Salvatore CISTERNINO, Dominique BREMOND-GIGNAC, Joël SCHLATTER, Philippe-Henri SECRETAN
  • Publication number: 20240024293
    Abstract: The present application relates to methods for treatment of Rett syndrome comprising administering an effect amount of nomethiazoles to a subject need thereof.
    Type: Application
    Filed: February 3, 2020
    Publication date: January 25, 2024
    Inventors: Doug COWART, Craig HARTMAN
  • Publication number: 20240024294
    Abstract: The disclosure provides compositions and methods for delaying the onset of delivery in a pregnant subject, such as a pregnant human subject, that is undergoing or at risk of undergoing preterm labor at a gestational age of from about 24 weeks to about 34 weeks. Using the compositions and methods described herein, such subjects may be administered atosiban in combination with a prostaglandin F2? (PGF2?) antagonist. Exemplary PGF2? receptor antagonists that may be used for the treatment or prevention of preterm labor as described herein include 1,3-thiazolidine-2-carboxamide compounds, such as (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate or a pharmaceutically acceptable salt thereof (e.g., (3S)-3-({[(2S)-3-(biphenyl-4-ylsulfonyl)-1,3-thiazolidin-2-yl]carbonyl}-amino)-3-(4-fluorophenyl)propyl L-valinate hydrochloride). The compositions and methods described herein provide various clinical benefits.
    Type: Application
    Filed: November 16, 2021
    Publication date: January 25, 2024
    Inventor: Jean-Pierre GOTTELAND
  • Publication number: 20240024295
    Abstract: A method for inhibiting hair growth in mammals using compositions containing thiazoiidine or quinoline carboxamide FP receptor antagonists. The compositions can be applied topically to the skin and/or hair. The compositions can (1) arrest hirsutism or hypertrichosis, (2) reverse hirsutism, hypertrichosis, and/or unwanted hair, and (3) prevent or limit hair growth including after hair removal by chemical or physical methods. These compositions can also be used to help prevent or to limit the degree of hair loss from chemotherapy/cytotoxic chemical agents or radiation.
    Type: Application
    Filed: December 10, 2021
    Publication date: January 25, 2024
    Inventor: Elise A. Olsen
  • Publication number: 20240024296
    Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
    Type: Application
    Filed: October 4, 2023
    Publication date: January 25, 2024
    Inventor: Kirk Patrick SEWARD
  • Publication number: 20240024297
    Abstract: A method for preventing or treating renal ischemia reperfusion injury or acute kidney injury associated with renal ischemia reperfusion injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
    Type: Application
    Filed: March 29, 2023
    Publication date: January 25, 2024
    Inventors: Sanford Markowitz, Ki Beom Bae, Hye Jung Kim, Sun-Hee Kim
  • Publication number: 20240024298
    Abstract: Disclosed are methods and compositions for treating a human papillomavirus (HPV)-related disease or cancer in an individual in need thereof. The method may comprise administering a glucosylceramide synthase (GCS) inhibitor to the individual, for example, miglustat, eligustat, venglustat, T-036, and combinations thereof. The disclosed methods and compositions may be used to treat cancers such as cervical cancer, oropharyngeal cancer, vulvar cancer, anal cancer, penile cancer, vaginal cancer, rectal cancer, squamous cell carcinoma, adenocarcinoma, head and neck cancer, or skin or mucosal lesions such as a common wart, a genital wart, a respiratory wart, a plantar wart, a subungual wart, a periungual wart, a flat wart, and combinations thereof.
    Type: Application
    Filed: July 21, 2023
    Publication date: January 25, 2024
    Inventors: Susanne Wells, Taylor Lange, Kanimozhi Vairamani
  • Publication number: 20240024299
    Abstract: The spleen clears rigid erythrocytes from the circulation. Drug-induced stiffening of Plasmodium falciparum intra-erythrocytic sexual stages (mature gametocytes) is therefore expected to block the transmission of malaria By screening 13 555 compounds with spleen-mimetic microfilters, the inventors identified 82 compounds that stiffen mature gametocytes. Eight active families were identified, including known anti-malarial, antimicrobial or anticancer agents, amongst others. Hit prioritization based on accessible safety and pharmacokinetics data in humans identified 3 leading candidates. NITD609 displayed killing and stiffening effects (IC50 of 100 and 50 nM, respectively), while TD-6450 and L-THP had a pure or predominant stiffening effect (IC50 of 600 and 5 nM, respectively). These values are lower than or close to peak plasma concentrations in humans. Clinical trials with these strong malaria transmission-blocking candidates are envisioned.
    Type: Application
    Filed: December 13, 2021
    Publication date: January 25, 2024
    Inventors: Pierre BUFFET, Papa Alioune NDOUR, Mario CARUCCI, Julien DUEZ
  • Publication number: 20240024300
    Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 25, 2024
    Applicant: ARCUTIS BIOTHERAPEUTICS, INC.
    Inventor: David W. Osborne
  • Publication number: 20240024301
    Abstract: Provided herein are methods of tipifarnib in combination with a PI3K inhibitor, such as alpelisib, for treating, preventing or managing head and neck squamous cell carcinoma (HNSCC).
    Type: Application
    Filed: July 20, 2023
    Publication date: January 25, 2024
    Inventors: Francis Burrows, Mollie Leoni, Shivani Malik, Vishnu S. Mishra, Alison Smith, Harris Soifer
  • Publication number: 20240024302
    Abstract: Provided herein are methods of preventing, mitigating, decreasing, reversing and/or treating Arrhythmogenic Cardiomyopathy (ACM) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, a compounds of Formula II, or a compound of Formula III (I) (II), (III) wherein R1, R2, R3, n, R4, R4a, R5, m, R6, R7, and p are as defined herein.
    Type: Application
    Filed: October 25, 2021
    Publication date: January 25, 2024
    Inventors: Jeffrey E. SAFFITZ, Bruce D. HAMMOCK, Sung Hee HWANG
  • Publication number: 20240024303
    Abstract: Methods of treating cancer related conditions using anamorelin are described.
    Type: Application
    Filed: June 22, 2023
    Publication date: January 25, 2024
    Inventors: William MANN, John FRIEND, William POLVINO, Suzan ALLEN, Ming LU, Elizabeth DUUS, Ruben Giorgino, Enrico Baroni
  • Publication number: 20240024304
    Abstract: This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.
    Type: Application
    Filed: April 28, 2023
    Publication date: January 25, 2024
    Applicant: EMORY UNIVERSITY
    Inventors: Kerry J. Ressler, Raul Andero Gali
  • Publication number: 20240024305
    Abstract: Methods of improving visual endpoints related to retina-associated disease with CCR3 modulating agents are provided. An example of such an endpoint is visual acuity. Retina-associated diseases upon which visual acuity and other visual endpoints may be improved include retinopathy of prematurity, age-related macular degeneration, central retinal vein occlusion, and diabetic retinopathy.
    Type: Application
    Filed: February 16, 2023
    Publication date: January 25, 2024
    Inventors: Laura Corradini, Sam Jackson, Karoly Nikolich
  • Publication number: 20240024306
    Abstract: The present disclosure relates to a process for preparing arimoclomol, arimoclomol citrate and key intermediates, such as ORZY-01, thereof. The disclosure further relates to a process for preparing high purity arimoclomol citrate and methods of using the same.
    Type: Application
    Filed: May 31, 2023
    Publication date: January 25, 2024
    Inventors: Zhe ZHANG, Mark READ, Elisabeth Vang CARSTENSEN, Marco POPPE, Andreas PELZ
  • Publication number: 20240024307
    Abstract: A combination in only one dosage unit the drugs desloratadine and betamethasone, which represents a set of important technological challenges due to the physicochemical properties and the difference in dosage to ensure the obtaining of a stable product for the treatment of allergic and inflammatory processes in a subject.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 25, 2024
    Inventors: Cecilia Jannette MUÑOZ MARTINEZ, Claudia Delfina FARFÁN SALAZAR, Sixto Serafín ESPINOZA LEÓN, Jorge Alejandro GONZÁLEZ CANUDAS, Paola Yazmín OLLERVIDES RUBIO
  • Publication number: 20240024308
    Abstract: TLR7/8 antagonists can be used to treat coronavirus infections, including COVID-19, alone or in combination with one or more additional therapeutic agents.
    Type: Application
    Filed: May 14, 2021
    Publication date: January 25, 2024
    Applicant: Merck Healthcare KGaA
    Inventor: Julie A. DEMARTINO
  • Publication number: 20240024309
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Application
    Filed: September 27, 2023
    Publication date: January 25, 2024
    Inventor: Herriot Tabuteau
  • Publication number: 20240024310
    Abstract: The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
    Type: Application
    Filed: March 1, 2023
    Publication date: January 25, 2024
    Inventors: Tetsuro Kikuchi, Taro Iwamoto, Tsuyoshi Hirose
  • Publication number: 20240024311
    Abstract: A controlled release pharmaceutical dosage form that improve tolerability by reducing incidence of side effect associated with a Selexipag or its active metabolite contained in the dosage form comprising a release rate controlling ingredient in addition to the Selexipag or its active metabolite that govern a release of the Selexipag or its active metabolite from the dosage form, wherein the dosage form after administration to a mammal in fasting condition providing a. a mean or median Tmax of at least greater than 2 hours for the Selexipag and/or at least greater than 3.5 hours for the active metabolite of the Selexipag, and/or b. at least 20% lower Cmax for Selexipag and/or it's active metabolite compared to Cmax obtained after administration of the same amount of an immediate release dosage form of Selexipag or its active metabolite in fasting condition.
    Type: Application
    Filed: February 2, 2020
    Publication date: January 25, 2024
    Inventor: Jayendrakumar Dasharathlal Patel
  • Publication number: 20240024312
    Abstract: The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof. It also relates to controlling nitrosamine impurity, 7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP) in the composition, wherein the NTTP does not exceed the FDA's established acceptable intake limit of 0.37 ppm per day at release and during shelf-life.
    Type: Application
    Filed: October 4, 2023
    Publication date: January 25, 2024
    Applicant: ZYDUS LIFESCIENCES LIMITED
    Inventors: Muthaiyyan Essakimuthu Kannan, Jitendra Rameshchandra Patel, Saurin Mukundbhai Amin, Sachin Gahoi
  • Publication number: 20240024313
    Abstract: The disclosure is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. The disclosure is also directed to pharmaceutical compositions containing compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof, and uses of the pharmaceutical compositions in treating diseases, conditions, and disorders associated with fatty acid amide hydrolase (FAAH) activity.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 25, 2024
    Inventors: Ju SHI, Sheryl COPPOLA, Polly Rae PINE, Matthew BOYLAN, Thomas Wesley STOREY
  • Publication number: 20240024314
    Abstract: Therapeutic methods and pharmaceutical compositions for treating splenomegaly in a human subject are described. In certain embodiments, the invention includes therapeutic methods of treating splenomegaly using a BTK inhibitor.
    Type: Application
    Filed: January 8, 2021
    Publication date: January 25, 2024
    Applicant: Telios Pharma, Inc.
    Inventor: Wayne Philip Rothbaum
  • Publication number: 20240024315
    Abstract: The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor: (Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.
    Type: Application
    Filed: April 3, 2023
    Publication date: January 25, 2024
    Applicant: NewAmsterdam Pharma B.V.
    Inventors: John FORD, Patrick ROUND, John KASTELEIN, Atsuhiro KAWAGUCHI, Koichi TOMIYASU, Kozo OKA
  • Publication number: 20240024316
    Abstract: There is a method of treating or preventing pulmonary arterial hypertension (PAH) or associated pulmonary arterial hypertension (APAH) in a patient. The method has the step of systemically administering to the patient a therapeutically effective amount of one or more compounds: (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate or a pharmaceutically acceptable salt thereof, or (S)-8-(2-amino-6-((R)-1-(5-chloro-[1,1?-biphenyl]-2-yl)-2,2,2-trifluoroeth-oxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylic acid or a pharmaceutically acceptable salt thereof, or a combination of the foregoing. There is also a method of treating or preventing PAH or APAH in a patient by systemically administering a therapeutically effective amount of a THP1 inhibitor from about 1 mg/kg/day to about 50 mg/kg/day. There is a method for treating PAH or APAH in a patient with a single daily dose.
    Type: Application
    Filed: January 4, 2023
    Publication date: January 25, 2024
    Inventors: Magdalena Alonso-Galicia, David Carpenter, Thomas Pack, Melissa Rhodes, Julie Rurka, Stephen Wring
  • Publication number: 20240024317
    Abstract: The present invention is directed to a combination treatment using bosentan and a checkpoint inhibitor that is effective in treating cancer or inhibiting the proliferation of tumor cells in a subject and/or that can initiate, enhance or prolong the immune response to tumor cells.
    Type: Application
    Filed: December 9, 2021
    Publication date: January 25, 2024
    Inventors: John D. MARTIN, Triantafyllos STYLIANOPOULOS, Fotios MPEKRIS, Myrofora PANAGI, Chysovalantis VOUTOURI, Andreas STYLIANOU
  • Publication number: 20240024318
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: May 5, 2023
    Publication date: January 25, 2024
    Inventors: Yi ZHANG, Paul R. Fleming, Xiao Zhu
  • Publication number: 20240024319
    Abstract: The present invention relates to a use of BI853520 or a pharmaceutically acceptable salt thereof in preparing drugs for treating tumors in combination with chemotherapeutic drugs.
    Type: Application
    Filed: July 5, 2023
    Publication date: January 25, 2024
    Inventors: Zaiqi Wang, Jiangwei Zhang